LNSR - NASDAQ
LENSAR, Inc.
$5.74
-2.0%LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company was incorporated in 2004 and is headquartered in Orlando, Florida.
At a Glance
Live SnapshotLENSAR, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Cash Flow Quality Insight
Deteriorating cash generation: Both declining FCF and weak conversion rate signal fundamental challenges. Investigate margin pressure, rising costs, or working capital issues.
LENSAR, Inc. Cash Flow Statement
LNSR • NASDAQ
| LENSAR, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||
-34.3M | -31.4M | -14.4M | -19.9M | -19.6M | -19.8M | -14.7M | -12.6M | |
4.5M | 3.9M | 3.5M | 3.4M | 2.8M | 2.6M | 3.9M | 4.6M | |
0.0 | 0.0 | 0.0 | 0.0 | 527K | 57K | -78K | 0.0 | |
3.1M | 2.7M | 5.5M | 6.6M | 6.9M | 9M | 102K | 1.3M | |
10.7M | 25.6M | 3.4M | 618K | 517K | 505K | 537K | 9.1M | |
(42K) | (24K) | (18K) | (3K) | (19K) | (0.0) | (0.0) | (0.0) | |
1.1M | -3M | -7.8M | -5.6M | -42K | -6.2M | -2.4M | 5.9M | |
-14.8M | -2.3M | -9.7M | -14.9M | -9M | -13.8M | -12.6M | -1.9M | |
INVESTING ACTIVITIES | ||||||||
-83K | -156K | -236K | -115K | -354K | -366K | -2.1M | -3.2M | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (40K) | (0.0) | -644K | |
-11.9M | -10.2M | -3.9M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
13.2M | 8.2M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -644K | |
(1.3M) | -2.2M | -4.2M | -115K | -354K | -326K | -2.1M | -3.9M | |
FINANCING ACTIVITIES | ||||||||
258K | 58K | 0.0 | 408K | 361K | 39.5M | 3.8M | 3.9M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 12.4M | 13.2M | 3.5M | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -1.9M | -31K | -198K | |
10M | 20K | 5.9M | -2.4M | 0.0 | 0.0 | -1.1M | -214K | |
10.3M | 78K | 19.8M | -2M | 361K | 50M | 15.9M | 7M | |
CASH FLOW SUMMARY | ||||||||
-3.3M | -4.4M | 5.9M | -17M | -9M | 35.9M | 1.3M | 1.2M | |
16.3M | 20.6M | 14.7M | 31.6M | 40.6M | 4.7M | 3.4M | 2.2M | |
13M | 16.3M | 20.6M | 14.7M | 31.6M | 40.6M | 4.7M | 3.3M | |
-14.9M | -2.4M | -9.9M | -15M | -9.3M | -14.2M | -14.7M | -5.1M |
SEC Filings
LNSR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 29, 2026 | May 25, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 08, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 08, 2026 | May 08, 2026 | 2026 | |
10-K/A 10-K/A 2025 FY (Amended) FY | April 30, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | April 15, 2026 | April 10, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 31, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 31, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 17, 2026 | March 16, 2026 | 2026 | |
8-K/A 8-K/A 2026 (Amended) N/A | March 13, 2026 | March 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 12, 2026 | March 12, 2026 | 2026 |
Related Guides
Continue your LNSR research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.